trending Market Intelligence /marketintelligence/en/news-insights/trending/vbvw2pk07mik43ug1ijt3w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Sosei beefs up board with R&D experts

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Sosei beefs up board with R&D experts

Sosei Group Corp. nominated Michael Hayden, Kuniaki Kaga and David Roblin as external directors to the company's board.

Hayden was previously global research and development president and chief scientific officer at Teva Pharmaceutical Industries Ltd.; Kaga was formerly senior managing executive officer at Mitsubishi Tanabe Pharma Corp.; and Roblin was formerly senior vice president, head of research and chief medical officer for Europe research and development at Pfizer Inc.

The Tokyo-listed biopharmaceutical company expects the new appointees to "provide experienced oversight" of the company's research and development pipeline among other services, the company said in a press release.

Meanwhile, Declan Doogan is retiring as an external director of the company.

The nominations have been submitted for approval at the company's shareholders meeting June 22.

Sosei develops and sells biopharmaceutical products internationally.